CJC-1295, Ipamorelin, MOTS-c and Tesamorelin: How These Peptides Compare

The short answer is that cjc 1295 ipamorelin mots-c and tesamorelin are four distinct peptides with four different mechanisms, and only one of them is FDA-approved for any human use. CJC-1295 and ipamorelin are growth hormone secretagogues sold as research chemicals, MOTS-c is a mitochondrial-derived peptide studied for metabolic effects, and tesamorelin is a prescription GHRH analog approved for a narrow medical indication. None of the four is a general-purpose weight loss or anti-aging drug.

Quick Comparison of All Four Peptides

CJC-1295 comes in two forms that behave very differently, which is a frequent source of confusion in online discussions.

Peptide	Class	Main research focus	Approximate half-life	US regulatory status
CJC-1295 with DAC	GHRH analog bound to a drug affinity complex	Long-acting growth hormone and IGF-1 elevation	About 6 to 8 days	Not FDA-approved; research use only
CJC-1295 without DAC (Mod GRF 1-29)	GHRH analog	Short pulses of growth hormone release	About 30 minutes	Research use only
Ipamorelin	Selective ghrelin receptor (GHS-R1a) agonist	Growth hormone release with fewer off-target hormone effects	About 2 hours	Research use only
MOTS-c	Mitochondrial-derived peptide (16 amino acids)	Insulin sensitivity, lipid metabolism, AMPK signaling	Not firmly established in humans	Research use only
Tesamorelin	GHRH analog (GRF 1-44)	Visceral fat reduction in HIV-associated lipodystrophy	About 26 to 38 minutes	FDA-approved as Egrifta SV

What Each Peptide Does in the Body

CJC-1295

CJC-1295 mimics growth hormone-releasing hormone and binds GHRH receptors in the pituitary, prompting the body to release its own growth hormone. The DAC form attaches to albumin in the blood, which stretches a 30-minute signal into a week-long one. The long half-life of CJC-1295 with DAC also raises IGF-1 more persistently, which is why bloodwork monitoring is standard in research settings.

Ipamorelin

Ipamorelin activates the ghrelin receptor, a separate pathway that also triggers growth hormone release. It was engineered to be selective, producing smaller shifts in cortisol, prolactin, and appetite than older secretagogues such as GHRP-6. Because ipamorelin uses a different receptor than CJC-1295, the two are frequently combined.

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA and studied primarily for metabolic regulation. Animal and early human research has examined insulin sensitivity, fat oxidation, and exercise capacity. Human evidence for MOTS-c remains thin, and researchers have not settled on a standard dosing range.

Tesamorelin

Tesamorelin is a GHRH analog approved by the FDA as Egrifta SV for reducing visceral abdominal fat in adults with HIV and lipodystrophy. It is given as a once-daily subcutaneous injection. Researchers have also studied tesamorelin in mild cognitive impairment, but that use is still investigational.

CJC-1295 Ipamorelin vs Tesamorelin: Where the Overlap Ends

CJC-1295 and tesamorelin are both GHRH analogs, so they push the same pituitary button. The cjc-1295 ipamorelin vs tesamorelin distinction usually comes down to duration and approval status rather than a fundamentally different mechanism.

Ipamorelin works through the ghrelin receptor instead, which is why it complements rather than duplicates a GHRH analog. MOTS-c does not act on the pituitary at all, because it influences signaling inside cells; MOTS-c is therefore not a replacement for any growth hormone peptide.

Stacking These Peptides

A cjc 1295 ipamorelin tesamorelin stack is less logical than it first appears, because CJC-1295 and tesamorelin overlap almost completely. Running CJC-1295 and tesamorelin together mostly adds cost and injection burden without activating a new pathway.

• CJC-1295 plus ipamorelin: the classic pairing, combining GHRH signaling with ghrelin receptor signaling.
• Ipamorelin plus tesamorelin: mechanistically sensible, but no published human trials have tested the combination.
• MOTS-c on its own or alongside: usually treated as a separate metabolic experiment rather than part of a growth hormone protocol.

Dosing Ranges Reported in Research and Community Protocols

The table below reflects doses reported in published research and in community discussions. It is not medical guidance, and no clinician has approved these combinations.

Compound	Reported range	Frequency	Notes
CJC-1295 with DAC	1 to 2 mg	Once or twice weekly	Long half-life allows accumulation
CJC-1295 without DAC	About 100 mcg	1 to 3 times daily	Often paired with ipamorelin
Ipamorelin	100 to 300 mcg	1 to 3 times daily	Commonly dosed before bed
MOTS-c	5 to 10 mg	2 to 3 times weekly in research protocols	Human dosing is not established
Tesamorelin (Egrifta SV)	1.4 mg	Once daily	Label dose for HIV-associated lipodystrophy

Compounded blends are especially difficult to evaluate, because label accuracy and sterility vary widely among unregulated suppliers.

What People Report vs. What Studies Show

Most cjc-1295 ipamorelin results before and after reports circulating online are self-reported logs with no bloodwork and no control group. Those logs commonly describe better sleep, faster recovery from training, and noticeable changes in appetite.

Controlled data is strongest for tesamorelin, where clinical trials in HIV-associated lipodystrophy showed meaningful reductions in visceral fat over 26 to 52 weeks. CJC-1295, ipamorelin, and MOTS-c have far less human data, and much of what exists comes from small studies or animal models.

Threads on cjc-1295 and ipamorelin reddit often mention water retention, tingling in the hands, and injection site irritation. Water retention, tingling, and irritation at the injection site are usually described as mild and reversible after the peptide is stopped.

Safety and Legal Considerations

• CJC-1295, ipamorelin, and MOTS-c are not FDA-approved for human use and are legally sold only for laboratory research.
• Tesamorelin is FDA-approved, but only for HIV-associated lipodystrophy and only by prescription.
• Elevated IGF-1 is a shared concern across all growth hormone-related peptides, including tesamorelin.
• Peptides purchased online may be mislabeled, underdosed, or contaminated.
• People with a history of cancer, who are pregnant, or who have diabetic retinopathy should speak with a healthcare professional before considering these compounds.

Research peptides are not substitutes for approved medical treatment, and any decision about them belongs with a licensed clinician.

Bottom Line

CJC-1295 and ipamorelin are unapproved research peptides that raise growth hormone through two different receptors. MOTS-c is a mitochondrial peptide with promising metabolic research and very little human data. Tesamorelin is the only one of the four with FDA approval, and that approval is limited to visceral fat reduction in adults with HIV and lipodystrophy.

Stacking CJC-1295 with tesamorelin duplicates the same pathway rather than multiplying the effect. Anyone considering these peptides should discuss the risks with a licensed healthcare professional and rely on laboratory bloodwork rather than online before-and-after photos.

COMMON QUESTIONS

Frequently Asked Questions

Is CJC-1295 or ipamorelin FDA-approved?

No. CJC-1295, ipamorelin, and MOTS-c are not FDA-approved for human use in the United States and are sold legally only as laboratory research chemicals. Tesamorelin is the only peptide in this group with FDA approval, marketed as Egrifta SV for visceral fat reduction in adults with HIV-associated lipodystrophy.

Can you stack tesamorelin with CJC-1295 and ipamorelin?

Stacking tesamorelin with CJC-1295 duplicates the same GHRH pathway, since both are GHRH analogs, so the combination adds cost and injection burden without adding a new mechanism. Ipamorelin does use a different receptor and is commonly paired with a GHRH analog, but no published human trials have tested a tesamorelin, ipamorelin, and CJC-1295 blend together.

What is the typical dosage of a tesamorelin, ipamorelin and CJC-1295 blend?

There is no standard or approved dosage for a blend of these peptides, because such blends are unregulated research products. The FDA-labeled tesamorelin dose is 1.4 mg once daily, while research and community protocols for CJC-1295 and ipamorelin vary widely and are not established medical guidance. Anyone considering these compounds should consult a licensed healthcare professional rather than relying on vendor instructions.